{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:56:59Z","timestamp":1773129419306,"version":"3.50.1"},"reference-count":48,"publisher":"LLC Obyedinennaya Redaktsiya","issue":"12","license":[{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To assess the results of following up patients with chronic myeloid leukemia (CML) and a deep molecular response (MR) without tyrosine kinase inhibitor (TKI) therapy. Subjects and methods. The reasons for TKI discontinuation in 70 patients with CML and a deep MR of more than 1 year\u2019s duration were adverse events, pregnancy, and patients\u2019 decision. Information was collected retrospectively and prospectively in 2008-2016. Results. The median follow-up after TKI therapy discontinuation was 23 months (2 to 100 months). At 6, 12 and 24 months after TKI therapy discontinuation, the cumulative incidence of major MR (MMR) loss was 28, 41 and 48%, respectively; the survival rates without TKI therapy were 69, 50, and 39%, respectively. MMR loss was noted in 28 (88%) patients at 12 months; it was not seen without TKI therapy at 2-year follow-up. Deaths due to CML progression were absent. The Sokal risk group was a reliable factor influencing MMR loss (p \u2264 0.05). The cumulative recovery rate for deep MR after resumption of TKI use was 73 and 100% at 12 and 24 months, respectively, with a median follow-up of 24 months (1 to 116 months). Deep MR recovered at a later time when the therapy was resumed more than 30 days after MMR loss. Conclusion. Safe follow-up is possible in about 50% of the patients with CML and stable deep MRs without TKI therapy. The introduction of this approach into clinical practice requires regular molecular genetic monitoring and organizational activities. Biological factors in maintaining remission after TKI discontinuation need to be separately studied.<\/jats:p>","DOI":"10.17116\/terarkh2017891286-96","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T12:16:14Z","timestamp":1518005774000},"page":"86-96","source":"Crossref","is-referenced-by-count":7,"title":["Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy"],"prefix":"10.26442","volume":"89","author":[{"given":"A G","family":"Turkina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E Yu","family":"Chelysheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V A","family":"Shuvaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G A","family":"Gusarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A V","family":"Bykova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O A","family":"Shukhov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A N","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M V","family":"Vakhrusheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S R","family":"Goryacheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L Yu","family":"Kolosova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P S","family":"Krasikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M S","family":"Fominykh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I S","family":"Martynkevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A O","family":"Abdullaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A B","family":"Sudarikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V G","family":"Savchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"key-10.17116\/terarkh2017891286-96-1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139337"},{"key":"key-10.17116\/terarkh2017891286-96-2","unstructured":"Turkina AG, Chelysheva EY. The strategy of chronic myeloid leukemia therapy: opportunities and prospects. Terapevticheskii arkhiv. 2013;7:4-9. (In Russ.)"},{"key":"key-10.17116\/terarkh2017891286-96-3","unstructured":"Zaritskii AY, Lomaia EG., Vinogradova OY, Druzhkova GA, Kruglov SS, Abakumov EM, Sokolova MA, Nemchenko IS, Zakharova ES, Kovalyova LG, Kolosheinova TI, Goryacheva SR, Kolosova LY, Vakhrusheva MV, Loriya SS, Chernova LA, Zakharova AV, Pospelova TI, Krylova IV, Lyamkina AS, Maciulaitiene ER, Kuznetsov SV, Chelysheva EY, Ivanova VL, Udalyeva VY, Shneider TV, Ogorodnikova YS, Zhuravlyov VS, Martynkevich IS, Domracheva EV, Afanasyev BV, Abdulkadyrov KM, Khoroshko ND, Turkina AG. Pavlov IP. Results of multi-center study of gleevek therapy of patients with chrome myeloid leukemia in the chronic phase. Gematologiya i transfuziologiya 2007;2:13-17. (In Russ.)"},{"key":"key-10.17116\/terarkh2017891286-96-4","doi-asserted-by":"crossref","unstructured":"Abdulkadyrov KM, Shuvaev VA, Martynkevich IS, Fominykh MS, Potikhonova NA, Zotova II, Udalyeva VYu, Golovchenko RA, Shakhvorostova NV, Shikhbabaeva DI, Zenina MN, Tiranova SA, Kudryashova SA, Martynenko LS, Ivanova MP, Tsybakova NYu, Petrova EV, Polushkina LB, Kleina EV. Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy. Klinicheskaya onkogematologiya. 2016; 9(1):54-60. (In Russ)","DOI":"10.21320\/2500-2139-2016-9-1-54-60"},{"key":"key-10.17116\/terarkh2017891286-96-5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"key-10.17116\/terarkh2017891286-96-6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"key-10.17116\/terarkh2017891286-96-7","unstructured":"Shukhov OA. Molecular and cytogenetic characteristics of the Ph-positive clone in patients with chronic myeloid leukemia with prolonged exposure to tyrosine kinase inhibitors. The dissertation of the candidate of medical sciences. Moscow, 2015 (In Russ.)"},{"key":"key-10.17116\/terarkh2017891286-96-8","unstructured":"Lazareva OV, Turkina AG, Gusarova GA et al. The results of 12 years treatment of patients in late chronic phase of chronic myeloid leukemia by tyrosine kinase inhibitors after failure IFN-\u03b1. Sibirskii nauchnyi meditsinskii zhurnal. 2015;35(1):90-97. (In Russ.)"},{"key":"key-10.17116\/terarkh2017891286-96-9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-07-0844"},{"key":"key-10.17116\/terarkh2017891286-96-10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"key-10.17116\/terarkh2017891286-96-11","doi-asserted-by":"publisher","DOI":"10.21320\/2500-2139-2017-10-3-294-316"},{"key":"key-10.17116\/terarkh2017891286-96-12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.175"},{"key":"key-10.17116\/terarkh2017891286-96-13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"key-10.17116\/terarkh2017891286-96-14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"key-10.17116\/terarkh2017891286-96-15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.8899"},{"key":"key-10.17116\/terarkh2017891286-96-16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.1.319"},{"key":"key-10.17116\/terarkh2017891286-96-17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.1.319"},{"key":"key-10.17116\/terarkh2017891286-96-18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2947"},{"key":"key-10.17116\/terarkh2017891286-96-19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"key-10.17116\/terarkh2017891286-96-20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.51"},{"key":"key-10.17116\/terarkh2017891286-96-21","unstructured":"L\u00fctge I, Pfirrmann M, Stalljann I. Healthrelated quality of life in CML patients under nilotinib firts-line treatment: Results of a German sub-study within the ENEST 1st trial. Hematologica. 2015;100,Abstract P233."},{"key":"key-10.17116\/terarkh2017891286-96-22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.70"},{"key":"key-10.17116\/terarkh2017891286-96-23","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1091929"},{"key":"key-10.17116\/terarkh2017891286-96-24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"key-10.17116\/terarkh2017891286-96-25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-114900"},{"key":"key-10.17116\/terarkh2017891286-96-26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2317"},{"key":"key-10.17116\/terarkh2017891286-96-27","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e328352a8fe"},{"key":"key-10.17116\/terarkh2017891286-96-28","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1205479"},{"key":"key-10.17116\/terarkh2017891286-96-29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24186"},{"key":"key-10.17116\/terarkh2017891286-96-30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"key-10.17116\/terarkh2017891286-96-31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"key-10.17116\/terarkh2017891286-96-32","unstructured":"Chelysheva EY, Galaktionova AV, Turkina AG. The problem of adherence to therapy in chronic myeloid leukemia: understanding the patient and making a decision. Klinicheskaya onkogematologiya. Fundamental'nye issledovaniya i klinicheskaya praktika. 2013;6(2):157-165. (In Russ.)"},{"key":"key-10.17116\/terarkh2017891286-96-33","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.831092"},{"key":"key-10.17116\/terarkh2017891286-96-34","unstructured":"Chelysheva EY, Turkina AG, Gusarova GA, Bykova AV, Kuznetsov SV, Goryacheva SR, Sokolova MA, Novitskaya NV. The possibility of discontinuing therapy with tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Gematologiya i transfuziologiya. 2014; 59(1):70. (In Russ.)"},{"key":"key-10.17116\/terarkh2017891286-96-35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"key-10.17116\/terarkh2017891286-96-36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"key-10.17116\/terarkh2017891286-96-37","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"key-10.17116\/terarkh2017891286-96-38","doi-asserted-by":"crossref","unstructured":"Shah NP, Paquette R, Muller MC, Saussele S, Garc\u00eca-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A, Nicolini F-E, Mauro MJ, Mahon F-X, Rea D, Martin-Regueira P, Subar M, Li L, Lipton JH. Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CMLCP) and in stable deep molecular response (DMR) to dasatinib \u2014 the Dasfree Study. Blood. 2016;128(22): abstract 1895.","DOI":"10.1182\/blood.V128.22.1895.1895"},{"key":"key-10.17116\/terarkh2017891286-96-39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"key-10.17116\/terarkh2017891286-96-40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"key":"key-10.17116\/terarkh2017891286-96-41","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.115"},{"key":"key-10.17116\/terarkh2017891286-96-42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694265"},{"key":"key-10.17116\/terarkh2017891286-96-43","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2295-0"},{"key":"key-10.17116\/terarkh2017891286-96-44","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350951"},{"key":"key-10.17116\/terarkh2017891286-96-45","doi-asserted-by":"crossref","unstructured":"Mahon FX, Richter J, Guilhot J, Hjorth-Hansen, H., Almeida A., Janssen J, Mayer J, Porkka K, Panayiotidis P, Stromberg U, Berger MG, Diamond J, Ehrencrona H, Kairisto V, Machova Polakova K, Mueller MC, Mustjoki S, Hochhaus A, Pfirrmann M, Saussele S. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood. 2016;128(22): abstract 787.","DOI":"10.1007\/978-3-319-33198-0_13"},{"key":"key-10.17116\/terarkh2017891286-96-46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.48.5797"},{"key":"key-10.17116\/terarkh2017891286-96-47","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1132420"},{"key":"key-10.17116\/terarkh2017891286-96-48","unstructured":"Shuvaev VA, Abdulkadyrov KM, Turkina AG., Martynkevich IS., Chelysheva EY, Fominykh MS. Pharmacoeconomic analysis of chronic myeloid leukemia remission without treatment. Onkogematologiya. 2014;(3):16-24. (In Russ.)"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T20:35:04Z","timestamp":1603830904000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/32357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,15]]}},"URL":"https:\/\/doi.org\/10.17116\/terarkh2017891286-96","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,15]]}}}